Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
Abstract
Immunotherapy for glioblastoma (GBM) remains an intensive area of investigation. Given the seismic impact of cancer immunotherapy across a range of malignancies, there is optimism that harnessing the power of immunity will influence GBM as well. However, despite several phase 3 studies, there are still no FDA-approved immunotherapies for GBM. Importantly, the field has learned a great deal from the randomized studies to date. Today, we are continuing to better understand the disease-specific features of the microenvironment in GBM-as well as the exploitable antigenic characteristic of the tumor cells themselves-that are informing the next generation of immune-based therapeutic strategies. The coming phase of next-generation immunotherapies is thus poised to bring us closer to treatments that will improve the lives of patients with GBM.
Read the paper
Related studies
- Current state and future directions for deep learning based automatic seismic fault interpretation: A systematic review
- Physics of Partially Saturated Porous Media: Residual Saturation and Seismic-Wave Propagation
- Modern Imaging Using Seismic Reflection Data
- Effects of marine seismic surveys on free-ranging fauna: a systematic literature review
- A review of the recent seismic activity in the southern part of egypt (upper egypt)
- A review of research on mechanism of seismic attenuation and energy compensation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.